Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 12;9(11):3646.
doi: 10.3390/jcm9113646.

Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study from the FRANCOGYN Group

Tiphaine de Foucher  1 , Cecile Hennebert  1 , Yohan Dabi  2 , Lobna Ouldamer  3 , Vincent Lavoué  4 , Ludivine Dion  4 , Geoffroy Canlorbe  5 , Pierre Adrien Bolze  6 , François Golfier  6 , Cherif Akladios  7 , Lise Lecointre  7 , Yohan Kerbage  8 , Pierre Collinet  8 , Alexandre Bricou  9 , Xavier Carcopino  10 , Cyrille Huchon  11 , Emilie Raimond  12 , Olivier Graesslin  12 , Clémentine Owen  1 , Cyril Touboul  1 , Marcos Ballester  13 , Emile Darai  1 , Sofiane Bendifallah  1
Affiliations

Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study from the FRANCOGYN Group

Tiphaine de Foucher et al. J Clin Med. .

Abstract

The standard of care for patients with advanced cervical cancer (ACC) includes platinum-based chemotherapy. The concept of platinum sensitivity is a major prognostic factor for patients with ovarian cancer. The aim of this study was to validate the applicability of the platinum sensitivity concept to ACC patients, and to estimate its prognostic interest in terms of overall survival (OS) and pattern of recurrence (location, timing). Data of women with histologically proven FIGO 2019 stages IB3-IV ACC, treated between May 2000 and November 2017 with platinum-based regimens, were retrospectively abstracted from 12 institutions from the FRANCOGYN Group. Respective 3-year OSs were 52% (95% CI: 40.8%-66.8%), 21.6% (95% CI: 12.6%-37.2%), and 14.6% (95% CI: 4.2%-50.2%), in case of recurrence <6 months, between 6 and 17 months, and ≥18 months (p < 0.001). Risk of metastatic or multisite recurrence was significantly higher in case of recurrence <6 months, and risk of local or isolated infradiaphragmatic nodal recurrence was significantly higher in case of recurrence >18 months (p < 0.001). In multivariate analysis, platinum sensitivity status was a strong prognostic factor for OS after recurrence, independent of histological grade, lympho-vascular space involvement, final lymph node status, and treatment. Platinum sensitivity status may help to classify patients in three prognostic subgroups for OS after recurrence, and appears to be a strong prognostic factor correlated to the pattern of recurrence.

Keywords: advanced cervical cancer; platinum sensitivity; recurrence pattern.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. No part of this manuscript has already been published in another journal, and all the authors agree to share equal responsibility for its content.

Figures

Figure 1
Figure 1
Patients flowchart.
Figure 2
Figure 2
Overall survival after recurrence according to platinum sensitivity.
Figure 3
Figure 3
Median time to recurrence and overall survival according to platinum sensitivity.
Figure 4
Figure 4
Overall survival after recurrence according to recurrence risk group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. International Agency for Research on Cancer World Health Organization Cancer Today. [(accessed on 30 October 2020)]; Available online: http://gco.iarc.fr/today/home.
    1. Quinn M.A., Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W.T., Heintz A.P.M., Ngan H.Y.S., Pecorelli S. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. Off. Organ. Int. Fed. Gynaecol. Obstet. 2006;95(Suppl. 1):S43-103. doi: 10.1016/S0020-7292(06)60030-1. - DOI - PubMed
    1. Monk B.J., Tewari K.S., Koh W.J. Multimodality therapy for locally advanced cervical carcinoma: State of the art and future directions. J. Clin Oncol. 2007;25:2952–2965. doi: 10.1200/JCO.2007.10.8324. - DOI - PubMed
    1. Scatchard K., Forrest J.L., Flubacher M., Cornes P., Williams C. Chemotherapy for metastatic and recurrent cervical cancer. Cochrane Database Syst. Rev. 2012;10:CD006469. doi: 10.1002/14651858.CD006469.pub2. - DOI - PMC - PubMed
    1. Kitagawa R., Katsumata N., Ando M., Shimizu C., Fujiwara Y., Yoshikawa H., Satoh T., Nakanishi T., Ushijima K., Kamura T. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol. Oncol. 2012;125:307–311. doi: 10.1016/j.ygyno.2012.02.009. - DOI - PubMed

LinkOut - more resources